What Is Actually Changing In PacBio’s Fair Value Story? Analysts have lifted their fair value estimate for Pacific ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results , but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15 per share was 20.5% ...

Now that Pacific Biosciences has broken through the $1 level that avoids Nasdaq delisting for now, we can focus on what might be ahead: the near-term path to cash flow breakeven. PacBio’s biggest ...

Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP ...

MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the ...